Dublin, May 15, 2020 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive understanding and unprecedented access to the Precision medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
- In-depth understanding of Precision Medicine deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Precision Medicine agreements with numerous real life case studies
- Detailed access to actual Precision Medicine contracts entered into by leading biopharma companies
- Identify most active Precision Medicine dealmakers since 2014
- Insight into terms included in a Precision Medicine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
The report takes the reader through a comprehensive review Precision Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Precision Medicine partnering deals.
The report presents financial deal term values for Precision Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Precision Medicine partnering field; both the leading deal values and most active Precision Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1,000 online deal records of actual Precision Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Precision Medicine dealmaking.
- Chapter 1 provides an introduction to the report.
- Chapter 2 provides an overview of the trends in Precision Medicine dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
- Chapter 3 provides a review of the leading Precision Medicine deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
- Chapter 4 provides a comprehensive listing of the top 25 most active companies in Precision Medicine dealmaking with a brief summary followed by a comprehensive listing of Precision Medicine deals announced by that company, as well as contract documents, where available.
- Chapter 5 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
- Chapter 6 provides a comprehensive and detailed review of Precision Medicine partnering deals signed and announced since Jan 2014. The - Chapter is organized by specific Precision Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Precision Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Precision Medicine partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Precision Medicine technologies and products.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
- 1CellBiO
- 2bPrecise
- 2X Oncology
- 3D Systems
- 4D Pharma
- 20/20 GeneSystems
- 23andMe
- 48Hour Discovery
- A*STAR Agency for Science
- Technology and Research
- A*STAR Bioinformatics Institute
- A*STAR Bioprocessing Technology Institute
- A*STAR Genome Institute of Singapore
- Abbott Laboratories
- Abbvie
- Abcam
- Abcodia
- Abramson Cancer Center
- Academic Medical Center
- Accelerate Diagnostics
- AccuGenomics
- Accu Reference Medical Laboratory
- AC Immune
- Acumen Pharmaceuticals
- Adaptive Biotechnologies
- Adarza BioSystems
- ADC Therapeutics
- Admera Health
- Aduro BioTech
- Advanced Cell Diagnostics
- Advanced Nuclear Medicine Ingredients
- Advaxis
- Aelan Cell Technologies
- Aerocrine
- Affigen
- AFFiRiS
- Affymetrix
- Age Labs
- Agendia
- Agilent Technologies
- Agios Pharmaceuticals
- Air Force Research Laboratory
- AIT Laboratories
- Akers Biosciences
- AKESOgen
- Akili Interactive Labs
- Albert Einstein College of Medicine
- Alcyone Lifesciences
- Alector
- Alexion Pharmaceuticals
- Alion Pharmaceuticals
- Allele Biotechnology and Pharmaceuticals
- AlloSource
- Allscripts
- Almac Diagnostics
- Alpha Genomix Laboratories
- ALS Association
- ALS Finding a Cure Foundation
- Altor BioScience
- Alzeca Biosciences
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Alzheimers Research UK
- Amarantus BioSciences
- Amarna Therapeutics
- Ambiopharm
- American Association for Cancer Research
- American Association of Neuromuscular & Electrodiagnostic Medicine
- American Diabetes Association
- AmerisourceBergen
- Amgen
- AmorChem
- Amoy Diagnostics
- AmpTec
- AMRA
- Analytics Engines
- and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/ipmnvz
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900